STRATEGIC PARTNERSHIP OFFER: Open Bioengineering & AI Safety Architectures "Althea" (CRISPR-TTP) + "AMAGI" (Hardware-Enforced AI Safety)

This document presents an open architecture ecosystem declaration, inviting collaboration on two complementary, fully open frameworks: 1. "Althea" (CRISPR-TTP Bioengineering Platform)A fully open (CC0) bioengineering architecture for the treatment of fusion-driven cancers, with an initial focus on Ewing Sarcoma. The platform integrates: CRISPR-Cas9 genome editing of autologous dendritic cells (>94% efficiency, 17+9 MHC binders); Temporally Programmed Delivery (TTP) via MR-guided Focused Ultrasound (FUS) activating HOF nanoparticles (27 ± 3 nm, 1–2 mm spatial resolution); AI Co-pilot for real-time personalization (89.3% sgRNA prediction accuracy). Regulatory context: EMA: ATMP classification determined within EMA framework (Feb 11, 2026) FDA CBER: INTERACT meeting request submitted and confirmed (Feb 18, 2026) Russian Ministry of Health: Expert evaluation completed (Feb 19, 2026) 2. "AMAGI" (Hardware-Enforced AI Safety Architecture)A reference architecture designed to transform regulatory compliance from a procedural burden into structural guarantees for high-risk AI systems. Core features: Six immutable invariants (Physical Non-Bypassability, Irreducible TCB, Separation of Control, Immutability of Policy, Complete Mediation, Complete Audit Integrity); TTP Triad (Trigger → Programmable Delay → Localized Activation) as a universal safety primitive; Hardware components: SCC (Security Council Core), NIPU (Neuro-Immune Processing Unit), MEM (Self-Protecting Memory), Amagi-Q (post-quantum crypto); Alignment with EU AI Act, NIST AI RMF 1.0, ISO 26262 (ASIL-D) frameworks. Published Works:Both architectures are supported by over 25 peer-reviewed and public-domain documents on Zenodo, all with DOIs. Core principles are publicly disclosed as prior art. What We Offer: Open access to complete architectural specifications (CC0 / CC BY-NC) Regulatory-ready frameworks with documented agency interactions Flexible collaboration formats: research collaboration, licensing (S-APL), IP core integration, grant consortia, and advisory board participation Target Partners:Biotech companies, semiconductor firms, CROs, academic labs, hospitals, and funding organizations interested in co-developing mission-driven, ethically grounded technologies for life-critical applications.